Clearside Biomedical — Technical Presentation (November 2022)
45 slides from Clearside Biomedical's technical presentation, Nov 9, 2022
Slide 1: OASIS Phase 1/2a Clinical Trial Results
OASIS Phase 1/2a Clinical Trial Results November 9, 2022 TM Exhibit 99.3
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”
Slide 3: Promising CLS-AX Safety Results, Durability and Biologic Effect
SAFETY RESULTS Excellent safety profile at all doses and timepoints No Serious Adverse Events No dose limiting toxicities No Adverse Events from inflammation Source: Clearside data on file. | Extension Study interim data as of October 27, 2022. BIOLOGIC EFFECT Stable mean Best Corrected Visual Acuit
Slide 4: Leveraging a Highly Potent Pan-VEGF Inhibitor with Suprachoroidal Delivery
Leveraging a Highly Potent Pan-VEGF Inhibitor with Suprachoroidal Delivery CLS-AX (axitinib injectable suspension) for Suprachoroidal Use May improve the treatment landscape with potential safety, efficacy, durability, and adoption benefits Durable suprachoroidal suspension may reduce patient burden
Slide 5: Trial Design and Objectives
TRIAL DESIGN AND OBJECTIVES Open-label study with a primary endpoint to evaluate safety and tolerability of escalating single doses of CLS-AX administered through suprachoroidal injection following IVT aflibercept Wet AMD patients with >2 anti-VEGF treatments in the prior 4 months, reading center co
Slide 6: Why target this patient population?
Why target this patient population instead of treatment naïve or patients with controlled disease? Patients have a high need for effective therapy with lower treatment burden Minimizes the risk of false signals of biologic effect Facilitates assessment for biological effect in a difficult-to-treat n
Slide 7: Wet AMD Disease Characteristics
Wet AMD Disease Characteristics COHORT 1: 0.03 mg COHORT 2: 0.1 mg COHORT 3: 0.5 mg COHORT 4: 1.0 mg No. of participants 6 5 8 8 Mean age (range), years 81.8 (66-93) 78.2 (65-90) 86.3 (75-97) 76.5 (66-83) Mean baseline best corrected visual acuity (range), letters 59.0 (29-74) 65.6 (52-75) 58.5 (37-
Slide 8: Safety Results
Safety Results
Slide 9: CLS-AX Demonstrated a Positive Safety Profile in All Four Cohorts
3-Month Final Data & 6-Month Interim Data CLS-AX Demonstrated a Positive Safety Profile in All Four Cohorts Excellent Safety Profile at all doses and timepoints No serious adverse events (SAEs) No treatment emergent adverse events (TEAEs) related to study treatment No dose limiting toxicities No adv
Slide 10: Durability
/ Durability
Slide 11: OASIS (3 Month): Prior Anti-VEGF Therapies and All Additional Therapies
HORT 1: 0.03 mgCO COHORT 2: 0.1 mg COHORT 3: 0.5 mg COHORT 4: 1.0 mg Source: Clearside data on file. OASIS (3 Month): Prior Anti-VEGF Therapies and All Additional Therapies Cohorts 3 & 4: 11/16 (69%) of patients did not receive additional therapy to 3 months DURABILITY
Slide 12: OASIS (3 Month): Additional Therapies Per Protocol Criteria
HORT 1: 0.03 mgCO COHORT 2: 0.1 mg COHORT 3: 0.5 mg COHORT 4: 1.0 mg Excludes patients whose first additional therapy was not per protocol-defined criteria. Source: Clearside data on file. OASIS (3 Month): Prior Anti-VEGF Therapies and Additional Therapies Per Protocol Criteria Cohorts 3 & 4: 11/12
Slide 13: OASIS (3 Month): CLS-AX Reduced Treatment Burden Across All Cohorts
OASIS (3 Month): CLS-AX Reduced Treatment Burden Across All Cohorts Cohort Number of Participants Avg Monthly Injections Before CLS-AX Administration Avg Monthly Injections After CLS-AX Administration % Reduction 4 8 0.88 0.25 72.9 3 8 0.75 0.13 79.2 2 5 0.93 0.37 63.3 1 6 0.94 0.28 69.4 Reduction i
Slide 14: Extension Study (6 Month, Interim): All Additional Therapies
Extension Study (6 Month, Interim Data): Prior Anti-VEGF Therapies and All Additional Therapies COHORT 2: 0.1 mg COHORT 3: 0.5 mg COHORT 4: 1.0 mg Source: Clearside data on file. | Extension Study interim data as of October 27, 2022. Cohorts 3 & 4 No Additional Therapy To Month 4: 8/10 To Month 5: 7
Slide 15: Extension Study (6 Month, Interim): Per Protocol Criteria
Extension Study (6 Month, Interim Data): Prior Anti-VEGF Therapies and Additional Therapies Per Protocol Criteria COHORT 2: 0.1 mg COHORT 3: 0.5 mg COHORT 4: 1.0 mg Excludes patients whose first additional therapy was not per protocol-defined criteria. Source: Clearside data on file. | Extension Stu
Slide 16: 75% of Patients with No Additional Therapy to Month 6
Extension Study Interim Data: 75% of Patients with No Additional Therapy to Month 6 Extension Study (6 Month, Interim Data): Supplemental Anti-VEGF Injection-Free Rate up to Each Visit in Cohorts 3 and 4 Source: Clearside data on file. | Extension Study interim data as of October 27, 2022. Interim D
Slide 17: Extension Study: CLS-AX Reduced Treatment Burden Across Cohorts
Extension Study (6 Month, Interim Data): CLS-AX Reduced Treatment Burden Across Cohorts Reduction in Treatment Burden All Therapies Reduction in Treatment Burden Therapies Per Protocol Criteria Cohort Number of Participants Avg Monthly Injections Before CLS-AX Administration Avg Monthly Injections A
Slide 18: Biologic Effect in Cohorts 3 & 4
Biologic Effect in Cohorts 3 & 4
Slide 19: OASIS (3 Months): Stable Visual Acuity
Mean Best Corrected Visual Acuity Letter Score, Change from Screening OASIS (3 Months): Stable Visual Acuity Source: Clearside data on file. All Data Excluding Data After Additional Treatment
Slide 20: OASIS (3 Months): Stable Central Subfield Thickness
Mean Central Subfield Thickness, Change from Screening OASIS (3 Months): Stable Central Subfield Thickness Source: Clearside data on file. All Data Excluding Data After Additional Treatment
Slide 21: Extension Study (6 Month): Stable Visual Acuity
Mean Best Corrected Visual Acuity Letter Score, Change from Screening Extension Study (6 Month, Interim Data): Stable Visual Acuity All Data Excluding Data After Additional Treatment Source: Clearside data on file. | Extension Study interim data as of October 27, 2022. Cohort, n Scr Bl Mth 1 Mth 2 M
Slide 22: Extension Study (6 Month): Stable Central Subfield Thickness
Mean Central Subfield Thickness, Change from Screening Extension Study (6 Month, Interim Data): Stable Central Subfield Thickness Source: Clearside data on file. | Extension Study interim data as of October 27, 2022. Interim Data All Data Excluding Data After Additional Treatment Cohort, n Scr Bl Mt
Slide 23: Case Studies
Case Studies
Slide 24: Cohort 3, Subject 2: Biologic Effect in Sub-responder
Cohort 3, Subject 2: 89 prior anti-VEGF injections with persistent subfoveal fluid 1 month after aflibercept at screen Subretinal fluid gradually resolves through 4 months after CLS-AX with stable BCVA and improved CST 6 Month Case Study: CLS-AX Demonstrated Biologic Effect in anti-VEGF Sub-responde
Slide 25: Cohort 3, Subject 3: Durable Stability After CLS-AX
Cohort 3, Subject 3: 66 prior anti-VEGF injections with mild subfoveal and intraretinal fluid at screen Stable anatomy, BCVA and CST for 5 months after CLS-AX with no additional therapy (Month 6 visit pending) 5 Month Case Study: Durable Stability After CLS-AX Screening: Aflibercept BCVA 37, CST 228
Slide 26: Cohort 3, Subject 4: Durable Stability After CLS-AX
6 Month Case Study: Durable Stability After CLS-AX Cohort 3, Subject 4: 15 prior anti-VEGF injections with mild subfoveal fluid at screen Stable anatomy, BCVA and CST for 6 months after CLS-AX with no additional therapy Fovea (Macula Center) Stable, with no progression Screening: Aflibercept BCVA 42
Slide 27: Cohort 3, Subject 6: Durable Stability After CLS-AX
6 Month Case Study: Durable Stability After CLS-AX Screening: Aflibercept BCVA 72, CST 262 Month 3 BCVA 71, CST 207 Baseline: CLS-AX BCVA 71, CST 209 Month 6 BCVA 69, CST 200 Subretinal fluid Fibrovascular PED The cross section is superior to the fovea in the central subfield Cohort 3, Subject 6: 50
Slide 28: Summary and Next Steps
A ~ Summary’and Next Steps —
Slide 29: OASIS Results and Competitive Advantages
OASIS Results Competitive Advantages Safety (All Cohorts) Excellent Safety Profile at all doses and timepoints No SAEs, No TEAEs related to study treatment No dose limiting toxicities No AEs related to inflammation, vasculitis or vascular occlusion No vitreous “floaters” or dispersion of CLS-AX into
Slide 30: Plans for Continued Progress with CLS-AX
Plans for Continued Progress with CLS-AX Complete OASIS Extension Study Finalize Phase 2 Clinical Trial Plans Initiate Phase 2 Clinical Program Follow remaining patients in Extension Study Initiate in Q1 2023 Evaluate CLS-AX for wAMD and/or diabetic retinopathy Final data expected in Q1 2023 Expand
Slide 31: Arshad M. Khanani, MD, MA, FASRS
Sierra Eye Associates Managing Partner Director of Clinical Research Director of Fellowship University of Nevada, Reno School of Medicine Clinical Associate Professor Arshad M. Khanani, MD, MA, FASRS
Slide 32: TM
TM
Slide 33: Appendix
/ Appendix
Slide 34: Sources and Axitinib Pan-VEGF Inhibition
Sources: 1. Cabral T et al. Bevacizumab Injection in Patients with Neovascular Age-Related Macular Degeneration Increases Angiogenic Biomarkers. Ophthalmol Retina. 2018 January ; 2(1): 31–37. doi:10.1016/j.oret.2017.04.004. | 2. Lieu et al. The Association of Alternate VEGF Ligands with Resistance t
Slide 35: Plasma CLS-AX at or below level of detection
Plasma CLS-AX at or below level of detection Rabbit Model Values: area under the curve ratios, SCS / IVT SCS : 1 mg/eye, 100 µL. | IVT: 1 mg/eye, 25 µL Single bilateral injection, 1-wk rabbit PK studies High Retina Levels: Sufficient to block VEGF pathway Low Plasma Levels: <1 ng/mL 11x SCS vs IVT R
Slide 36: Wet AMD Disease Characteristics
Wet AMD Disease Characteristics COHORT 1: 0.03 mg COHORT 2: 0.1 mg COHORT 3: 0.5 mg COHORT 4: 1.0 mg All Cohorts No. of participants 6 5 8 8 27 Mean age (range), years 81.8 (66-93) 78.2 (65-90) 86.3 (75-97) 76.5 (66-83) 80.9 (65-97) Mean baseline best corrected visual acuity (range), letters 59.0 (2
Slide 37: Anti-VEGF Treatments up to 3 Years Prior to Baseline
COHORT 3: 0.5 mg COHORT 4: 1.0 mg Source: Clearside data on file. Anti-VEGF Treatments up to 3 Years Prior to Baseline CLS-AX Administration
Slide 38: OASIS: Reason for Use of Additional Therapies
OASIS: Reason for Use of Additional Therapies COHORT SUBJECT # ADDITIONAL THERAPY VISIT REASON FOR ADDITIONAL THERAPY COHORT 1: 0.03 mg (N=6) 1 2 months post CLS-AX BCVA with exudation 3 2 months post CLS-AX 3 months post CLS-AX CST BCVA with exudation (not verified by reading center) 4 2 months pos
Slide 39: Cohort 3: Stable BCVA and CST to 3 Months
COHORT 3 (0.5 mg): BCVA COHORT 3 (0.5 mg): CST Source: Clearside data on file. Cohort 3: Stable Best Corrected Visual Acuity and Central Subfield Thickness to 3 Months
Slide 40: Cohort 4: Stable BCVA and CST to 3 Months
COHORT 4 (1.0 mg): CST COHORT 4 (1.0 mg): BCVA Source: Clearside data on file. Dotted line = patient received additional therapy not per protocol (not reading center verified or physician discretion) Cohort 4: Stable Best Corrected Visual Acuity and Central Subfield Thickness to 3 Months
Slide 41: Extension Study: Demographics and Wet AMD History
Wet AMD Disease Characteristics COHORT 2: 0.10 mg COHORT 3: 0.50 mg COHORT 4: 1.0 mg All Cohorts No. of participants 2 7 5 14 Mean age (range), years 74.0 (70-78) 87.9 (81-97) 79.6 (74-83) 82.9 (70-97) Mean baseline best corrected visual acuity (range), letters 60.0 (52-68) 59.0 (37-74) 71.2 (69-74)
Slide 42: Extension Study: Reason for Use of Additional Therapies
Extension Study: Reason for Use of Additional Therapies (in Months 4, 5, 6) COHORT SUBJECT ADDITIONAL THERAPY VISIT REASON FOR ADDITIONAL THERAPY COHORT 2: 0.10 mg (N=2) 1 5 months post CLS-AX Macular hemorrhage COHORT 3: 0.5 mg (N=7) 2 6 months post CLS-AX BCVA with exudation 5 6 months post CLS-AX
Slide 43: Cohort 3 Interim Extension Study: Stable BCVA and CST
Cohort 3 Interim Extension Study: Stable Best Corrected Visual Acuity and Central Subfield Thickness Beyond 3 Months COHORT 3 (0.5 mg): BCVA COHORT 3 (0.5 mg): CST Source: Clearside data on file. | Extension Study interim data as of October 27, 2022. Dotted line = patient received additional therapy
Slide 44: Cohort 4 Interim Extension Study: Stable BCVA and CST
COHORT 4 (1.0 mg): CST COHORT 4 (1.0 mg): BCVA Source: Clearside data on file. | Extension Study interim data as of October 27, 2022. Dotted line = patient received additional therapy not per protocol (not reading center verified or physician discretion) Interim Data Cohort 4 Interim Extension Study
Slide 45: Dr. Khanani biography
Dr. Khanani founded the clinical research department at Sierra Eye Associates, which is now one of the leading clinical research centers in the country. He has served as a principal investigator for over 100 clinical trials and has been a top enroller in the country for multiple Phase 1-3 trials. In
Clearside Biomedical — Technical Presentation (November 2022) on 6ix